The EPS beat is entirely from a one-time asset sale, not recurring operations. Monitor the strategic alternatives process for a potential sale or merger, which is the primary catalyst. The cash runway into Q2 2027 provides a limited window for a deal to be consummated.
Price Chart
Executive Summary
Werewolf Therapeutics reported Q2 2026 net income of $3.7M ($0.08 EPS), a significant swing from a net loss of $18.0M in Q2 2025, driven by a $21.0M collaboration revenue from the sale of its JZP898 program to Jazz Pharmaceuticals. However, cash and cash equivalents dropped sharply to $22.0M from $46.5M at Q1 end, and the company continues to explore strategic alternatives with Piper Sandler, with no defined timeline or guarantee of a transaction. The reported EPS of $0.08 is a beat vs the consensus estimate of $-0.28, but this is entirely due to a non-recurring asset sale, not operational improvement, making the headline beat misleading for ongoing valuation.
Key Financial Metrics
Key Facts
- Reported Q2 2026 net income of $3.7M ($0.08 EPS) vs net loss of $18.0M ($-0.40 EPS) in Q2 2025.
- Revenue of $21.0M was entirely from the sale of the JZP898 program to Jazz Pharmaceuticals; no collaboration revenue in Q2 2025.
- Cash and cash equivalents fell to $22.0M as of June 30, 2026, from $46.5M as of March 31, 2026.
- Company expects to fund operations into Q2 2027 based on current operating plan.
- Company continues to explore strategic alternatives with Piper Sandler; no defined timeline or guarantee of a transaction.
- Debt fully repaid: total notes payable reduced to $0 from $28.2M at year-end 2025.
- Operating expenses (R&D + G&A) decreased to $13.8M from $17.5M in Q2 2025.
Financial Impact
Q2 2026 net income of $3.7M vs net loss of $18.0M in Q2 2025; cash burn of $24.5M from $46.5M to $22.0M in one quarter
Risk Factors
- Cash burn rate of ~$24.5M per quarter is unsustainable without a strategic transaction or additional financing.
- No defined timeline or guarantee of a successful strategic alternative, which could lead to significant dilution or a low-premium sale.
- Reliance on non-recurring collaboration revenue for profitability masks ongoing operating losses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001785530-26-000018 |
| Document: howl-20260731.htm | 0001785530-26-000018 |
| Document: 0001785530-26-000018-index-headers.html | 0001785530-26-000018 |
| Document: 0001785530-26-000018-index.html | 0001785530-26-000018 |
| Document: 0001785530-26-000018.txt | 0001785530-26-000018 |
| 8-K Data (Synthetic) | 0001785530-26-000018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-4/A | $0.9806 | awaiting T+5 | — | $1.02 (−4.02%) |
Sep 22, 2026 4w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $1.02 (−3.09%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $1.02 (+4.08%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $1.02 (+16.70%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $1.02 (+16.70%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $1.02 (−16.70%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $1.02 (+188.87%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $1.02 (+188.87%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $1.02 (−183.41%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $1.02 (−183.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers